{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:29:57Z","timestamp":1793896197889,"version":"4.8.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This <jats:italic>post hoc<\/jats:italic> analysis of the ANANKE study (NCT04272463) reports data on the long-term effectiveness of benralizumab between SEA patients with and without CRSwNP (<jats:italic>N<\/jats:italic>\u2009=\u200986 and <jats:italic>N<\/jats:italic>\u2009=\u200975, respectively) treated for up to 96 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patients achieving considerable reductions than No-CRSwNP patients (severe AER dropped by 100% and 95.6%, respectively). While lung function improvement was comparable at week 96, CRSwNP patients showed a faster response to benralizumab, with a rise of forced expiratory volume in 1\u2005s (FEV<jats:sub>1<\/jats:sub>) at 16 weeks that was maintained throughout the study. Median OCS daily dose decreased to 0.0\u2005mg in both groups at 96 weeks, but benralizumab OCS-sparing effect was faster in CRSwNP patients (median OCS dose was 0.0\u2005mg and 2.5\u2005mg in CRSwNP and No-CRSwNP patients respectively, at 48 weeks). Although asthma control test (ACT) median scores were comparable, greater proportions of CRSwNP patients displayed well-controlled asthma (ACT\u2009\u2265\u200920) than No-CRSwNP patients at all time points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings show benralizumab long-term effectiveness in SEA patients with and without CRSwNP, highlighting its superior and faster-acting benefits on asthma outcomes in presence of CRSwNP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1501196","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T08:15:29Z","timestamp":1742458529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study"],"prefix":"10.3389","volume":"6","author":[{"given":"Luisa","family":"Brussino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bracciale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Malerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Schino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Walter","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the severe asthma network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"JAA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/medsci7020027","article-title":"Regulation of interaction between the upper and lower airways in united airway disease","volume":"7","author":"Kanda","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9589","DOI":"10.1038\/s41598-020-66479-8","article-title":"Bidirectional association between asthma and chronic rhinosinusitis: two longitudinal follow-up studies using a national sample cohort","volume":"10","author":"Ryu","year":"2020","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/jpm12071096","article-title":"Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach","volume":"12","author":"Seccia","year":"2022","journal-title":"JPM"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.jaip.2022.04.039","article-title":"Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/cells13050384","article-title":"Eosinophilic asthma: pathophysiology and therapeutic horizons","volume":"13","author":"Hussain","year":"2024","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","article-title":"Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma","volume":"395","author":"Peters","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/jcm8091375","article-title":"Severe eosinophilic asthma","volume":"8","author":"Bakakos","year":"2019","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/alr.22064","article-title":"Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population: asthma onset and patient characteristics in CRS","volume":"8","author":"John Staniorski","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/BTT.S157183","article-title":"New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic","volume":"13","author":"Caminati","year":"2019","journal-title":"BTT"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109680","DOI":"10.1016\/j.clim.2023.109680","article-title":"Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients","volume":"253","author":"Bergantini","year":"2023","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.pupt.2020.101966","article-title":"Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma","volume":"64","author":"Menzella","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"key":"B25","unstructured":"2024 GINA MAIN REPORT"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"Characterization of Italian severe uncontrolled asthmatic patieNts key features when receiving benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"881218","DOI":"10.3389\/falgy.2022.881218","article-title":"Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis","volume":"3","author":"D\u2019Amato","year":"2022","journal-title":"Front Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12931-023-02439-w","article-title":"Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study","volume":"24","author":"Vultaggio","year":"2023","journal-title":"Respir Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.3390\/jcm13103013","article-title":"Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: a three-year real-life study","volume":"13","author":"Pini","year":"2024","journal-title":"JCM"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2301521","DOI":"10.1183\/13993003.01521-2023","article-title":"Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme","volume":"64","author":"Jackson","year":"2024","journal-title":"Eur Respir J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"205873842095085","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2023028","DOI":"10.23750\/abm.v94i1.13474","article-title":"Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study","volume":"94","author":"Santomasi","year":"2023","journal-title":"Acta Biomedica Atenei Parmensis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jaip.2022.02.002","article-title":"Personalized treatment of asthma: the importance of sex and gender differences","volume":"10","author":"Jenkins","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"00670","DOI":"10.1183\/23120541.00670-2021","article-title":"Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?","volume":"8","author":"Benoni","year":"2022","journal-title":"ERJ Open Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.3390\/jcm12103371","article-title":"Pathobiology of type 2 inflammation in asthma and nasal polyposis","volume":"12","author":"Pelaia","year":"2023","journal-title":"JCM"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1501196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T08:15:34Z","timestamp":1742458534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1501196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":36,"alternative-id":["10.3389\/falgy.2025.1501196"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1501196","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1501196"}}